{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:06Z","timestamp":1790369946314,"version":"4.1.0"},"reference-count":113,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma cells are uniquely dependent on proteostasis due to their exceptionally high immunoglobulin synthesis and protein turnover, rendering them hypersensitive to disruptions in protein degradation. Proteasome inhibitors targeting the 20\u00a0S catalytic core exploit this vulnerability and remain a therapeutic cornerstone in newly diagnosed and relapsed\/refractory settings, anchoring both triplet and quadruplet regimens that incorporate anti-CD38 monoclonal antibodies, immunomodulatory agents, antibody-drug conjugates, and nuclear export inhibitors. Beyond the 20\u00a0S core, emerging targets, including the 19\u00a0S regulatory particle, deubiquitinating enzymes, and the E1-E2-E3 ubiquitination cascade, offer opportunities to intensify proteotoxic stress and overcome resistance. Targeted protein degradation platforms, including CELMoDs, proteolysis targeting chimeras, molecular glues, and proteasome cap-recruiting chimeras, further expand the therapeutic repertoire. Compensatory stress responses involving autophagy, the unfolded protein response, and the bone marrow microenvironment modulate therapeutic vulnerability. Collectively, these advances position proteostasis not as a single druggable target but as an integrated therapeutic network amenable to rational, biomarker-informed combination strategies in multiple myeloma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000852","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:51Z","timestamp":1790366451000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Proteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens"],"prefix":"10.1097","volume":"32","author":[{"given":"Yan","family":"Song","sequence":"first","affiliation":[{"name":"Division of Hematologic Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poy","family":"Theprungsirikul","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology"},{"name":"Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gulla","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, FPO-IRCCS-Candiolo, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology"},{"name":"Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12943-025-02472-x","article-title":"Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"issue":"suppl 1","key":"R2-20260925","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/gerona\/glu049","article-title":"Proteostasis and the aging proteome in health and disease","volume":"69","author":"Morimoto","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","article-title":"The proteostasis network and its decline in aging","volume":"20","author":"Hipp","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10238-025-01713-z","article-title":"Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma","volume":"25","author":"Sedlacek","year":"2025","journal-title":"Clin Exp Med"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms22041526","article-title":"The roles of the ubiquitin- proteasome system in the endoplasmic reticulum stress pathway","volume":"22","author":"Qu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","article-title":"Mechanisms underlying ubiquitination","volume":"70","author":"Pickart","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"R8-20260925","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin- proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620717710171","article-title":"The potential of ixazomib, a second- generation proteasome inhibitor, in the treatment of multiple myeloma","volume":"8","author":"Brayer","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"R11-20260925","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/cc.4.2.1414","article-title":"Proteasome inhibition in the treatment of cancer","volume":"4","author":"Richardson","year":"2005","journal-title":"Cell Cycle"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"key":"R14-20260925","first-page":"2599","article-title":"Ubiquitin receptor PSMD4\/ Rpn10 is a novel therapeutic target in multiple myeloma","volume":"141","author":"Du","year":"2023","journal-title":"Blood"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1038\/onc.2017.172","article-title":"Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"36","author":"Song","year":"2017","journal-title":"Oncogene"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood.2025029358","article-title":"Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma","volume":"147","author":"Du","year":"2026","journal-title":"Blood"},{"issue":"suppl 1","key":"R17-20260925","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood-2025-2148","article-title":"The unique role of PSMD2\/ Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance","volume":"146","author":"Du","year":"2025","journal-title":"Blood"},{"key":"R18-20260925","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","article-title":"A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ ADRM1 as a therapy for cancer","volume":"24","author":"Anchoori","year":"2013","journal-title":"Cancer Cell"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"e0227727","DOI":"10.1371\/journal.pone.0227727","article-title":"Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties","volume":"15","author":"Anchoori","year":"2020","journal-title":"PLoS One"},{"key":"R20-20260925","doi-asserted-by":"crossref","first-page":"e0285221","DOI":"10.1371\/journal.pone.0285221","article-title":"Development and anticancer properties of Up284, a spirocyclic candidate ADRM1\/RPN13 inhibitor","volume":"18","author":"Anchoori","year":"2023","journal-title":"PLoS One"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1021\/jacs.5b02069","article-title":"A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells","volume":"137","author":"Trader","year":"2015","journal-title":"J Am Chem Soc"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.chembiol.2020.08.008","article-title":"Mechanistic studies of the multiple myeloma and melanoma cell-selective toxicity of the Rpn13-binding peptoid KDT-11","volume":"27","author":"Dickson","year":"2020","journal-title":"Cell Chem Biol"},{"issue":"8 suppl 1","key":"R23-20260925","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1158\/1538-7445.AM2025-2978","article-title":"PSMD6 is a promising therapeutic target in multiple myeloma","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"R24-20260925","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1182\/blood-2025-3926","article-title":"PSMD3 orchestrates metabolic reprogramming and immunogenic cell death in multiple myeloma","volume":"146","author":"Fang","year":"2025","journal-title":"Blood"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11","volume":"13","author":"Li","year":"2017","journal-title":"Nat Chem Biol"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D\u2019Arcy","year":"2011","journal-title":"Nat Med"},{"key":"R27-20260925","doi-asserted-by":"crossref","first-page":"26979","DOI":"10.1038\/srep26979","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","article-title":"Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells","volume":"23","author":"Das","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R29-20260925","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"R30-20260925","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI98765","article-title":"Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma","volume":"128","author":"Franqui-Machin","year":"2018","journal-title":"J Clin Invest"},{"key":"R31-20260925","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41388-021-02167-9","article-title":"Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"R32-20260925","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nm.4474","article-title":"A small-molecule inhibitor of the ubiquitin-activating enzyme for cancer treatment","volume":"24","author":"Hyer","year":"2018","journal-title":"Nat Med"},{"key":"R33-20260925","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","article-title":"Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma","volume":"133","author":"Zhuang","year":"2019","journal-title":"Blood"},{"key":"R34-20260925","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/bloodadvances.2019000181","article-title":"Amplification and overexpression of E2 ubiquitin conjugase UBE2T promote homologous recombination in multiple myeloma","volume":"3","author":"Alagpulinsa","year":"2019","journal-title":"Blood Adv"},{"issue":"11\u201312","key":"R35-20260925","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41417-018-0070-x","article-title":"High expression of UBE2T predicts poor prognosis and survival in multiple myeloma","volume":"26","author":"Zhang","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"R36-20260925","first-page":"e82571","article-title":"Analysis of ubiquitin- conjugating enzyme E2T (UBE2T) protein levels in the bone marrow biopsy specimens of patients with multiple myeloma","volume":"17","author":"Wang","year":"2025","journal-title":"Cureus"},{"key":"R37-20260925","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1038\/sj.onc.1207458","article-title":"Blockade of ubiquitin- conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib\/Proteasome inhibitor PS-341","volume":"23","author":"Chauhan","year":"2004","journal-title":"Oncogene"},{"key":"R38-20260925","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2011.05.039","article-title":"An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme","volume":"145","author":"Ceccarelli","year":"2011","journal-title":"Cell"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CAD.0b013e32835c0311","article-title":"Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation","volume":"24","author":"Park","year":"2013","journal-title":"Anticancer Drugs"},{"key":"R40-20260925","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cbt.10.6.12535","article-title":"Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways","volume":"10","author":"Saha","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R41-20260925","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"R42-20260925","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/cancers14184492","article-title":"CRL4CRBN E3 ligase complex as a therapeutic target in multiple myeloma","volume":"14","author":"Barankiewicz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R43-20260925","doi-asserted-by":"crossref","first-page":"14884","DOI":"10.1038\/s41598-019-51446-9","article-title":"Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide","volume":"9","author":"Huang","year":"2019","journal-title":"Sci Rep"},{"key":"R44-20260925","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"R46-20260925","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40364-025-00825-8","article-title":"Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma","volume":"13","author":"Kegyes","year":"2025","journal-title":"Biomark Res"},{"key":"R47-20260925","doi-asserted-by":"crossref","first-page":"110712","DOI":"10.1016\/j.isci.2024.110712","article-title":"Molecular glue-mediated targeted protein degradation: a novel strategy in small- molecule drug development","volume":"27","author":"Tan","year":"2024","journal-title":"iScience"},{"key":"R48-20260925","doi-asserted-by":"crossref","first-page":"15282","DOI":"10.1021\/acs.jmedchem.2c01218","article-title":"A versatile and sustainable multicomponent platform for the synthesis of protein degraders: proof-of-concept application to BRD4- degrading PROTACs","volume":"65","author":"Bhela","year":"2022","journal-title":"J Med Chem"},{"key":"R49-20260925","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"e20039","DOI":"10.1002\/anie.202520039","article-title":"Proteasome cap targeting chimeras for ubiquitination-independent targeted protein degradation","volume":"65","author":"Song","year":"2026","journal-title":"Angew Chem Int Ed Engl"},{"key":"R51-20260925","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/cancers11111793","article-title":"Proteostasis in the endoplasmic reticulum: road to cure","volume":"11","author":"Nam","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R52-20260925","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"R53-20260925","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R54-20260925","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"R55-20260925","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"R56-20260925","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and multiple myeloma","volume":"4","author":"Giuliani","year":"2011","journal-title":"Cancer Microenviron"},{"key":"R57-20260925","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","article-title":"Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast","volume":"75","author":"Reagan","year":"2015","journal-title":"Bone"},{"key":"R58-20260925","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/ijms22094462","article-title":"The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma","volume":"22","author":"Giannakoulas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R59-20260925","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"key":"R60-20260925","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe?","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R61-20260925","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces an anti-multiple myeloma immune response mediated by cGAS\/ STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"R62-20260925","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.2023022777","article-title":"Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma","volume":"143","author":"Gulla","year":"2024","journal-title":"Blood"},{"key":"R63-20260925","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"R64-20260925","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"R65-20260925","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"R66-20260925","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"R67-20260925","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"key":"R68-20260925","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"R69-20260925","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"R70-20260925","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in 5myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"R71-20260925","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"R72-20260925","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow- up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"key":"R73-20260925","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomized, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"R74-20260925","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2025.43.16_suppl.7540","article-title":"Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial","volume":"43","author":"Kumar","year":"2025","journal-title":"J Clin Oncol"},{"key":"R75-20260925","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"R76-20260925","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"R77-20260925","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"R78-20260925","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomized, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"R79-20260925","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"R80-20260925","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"R81-20260925","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"R82-20260925","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"R83-20260925","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"R84-20260925","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomized, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"key":"R85-20260925","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomized, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"R86-20260925","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long- term follow-up of the CASSIOPEIA randomized controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"key":"R87-20260925","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"R88-20260925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant- ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"R89-20260925","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation- eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomized, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"R90-20260925","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"R91-20260925","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomized, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"R92-20260925","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"R93-20260925","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomized phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"R94-20260925","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"R95-20260925","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/S2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomized, controlled trial","volume":"11","author":"Yong","year":"2024","journal-title":"Lancet Haematol"},{"key":"R96-20260925","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"R97-20260925","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","article-title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomized, open- label, phase 3 trial","volume":"26","author":"Hungria","year":"2025","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"R98-20260925","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2025.43.16_suppl.7546","article-title":"DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features","volume":"43","author":"Mateos","year":"2025","journal-title":"J Clin Oncol"},{"key":"R99-20260925","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per- week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"R100-20260925","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ajh.26261","article-title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk","volume":"96","author":"Richard","year":"2021","journal-title":"Am J Hematol"},{"key":"R101-20260925","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ejh.14223","article-title":"Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial","volume":"113","author":"Mateos","year":"2024","journal-title":"Eur J Haematol"},{"key":"R102-20260925","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41591-026-04282-0","article-title":"Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial","volume":"32","author":"Gay","year":"2026","journal-title":"Nat Med"},{"key":"R103-20260925","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"key":"R104-20260925","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"R105-20260925","first-page":"S187","article-title":"Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Lonial","year":"2021","journal-title":"Hemasphere"},{"key":"R106-20260925","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 2","key":"R107-20260925","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S2152-2650(23)01616-6","article-title":"OA-49 mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480- MM-002 trial","volume":"23","author":"Oriol","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"suppl 1","key":"R108-20260925","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2024-198408","article-title":"Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from the CC- 92480-MM-002 trial","volume":"144","author":"Sandhu","year":"2024","journal-title":"Blood"},{"issue":"supple 1","key":"R109-20260925","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2023-189907","article-title":"A phase 1\/2 study of carfilzomib, iberdomide, and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma","volume":"142","author":"Biran","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"R110-20260925","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1200\/JCO.2025.43.16_suppl.7553","article-title":"Carfilzomib, iberdomide, and dexamethasone (KID) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated results from phase 1\/2 study","volume":"43","author":"Biran","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"R111-20260925","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1200\/JCO.2026.44.16_suppl.7514","article-title":"Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma","volume":"44","author":"Kapoor","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"R112-20260925","first-page":"7532","article-title":"Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant- ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. J","volume":"43","author":"White","year":"2025","journal-title":"Clin Oncol"},{"issue":"suppl 17","key":"R113-20260925","first-page":"LBA7506","article-title":"Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial","volume":"44","author":"Richardson","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:07Z","timestamp":1790366467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":113,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000852","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}